Forcaltonin
recombinant salmon calcitonin
Table of contents
Overview
The marketing authorisation for Forcaltonin has been withdrawn at the request of the marketing authorisation holder.
Authorisation details
| Product details | |
|---|---|
| Name |
Forcaltonin
|
| Agency product number |
EMEA/H/C/000197
|
| Active substance |
Recombinant salmon calcitonin
|
| International non-proprietary name (INN) or common name |
recombinant salmon calcitonin
|
| Therapeutic area (MeSH) |
|
| Anatomical therapeutic chemical (ATC) code |
H05BA01
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Unigene UK Ltd.
|
| Revision |
0
|
| Date of issue of marketing authorisation valid throughout the European Union |
11/01/1999
|
| Contact address |
Unigene UK Limited
191 Sparrows Herne Bushey Heath Hertfordshire WD23 1AJ United Kingdom |
Product information
20/11/2008 Forcaltonin - EMEA/H/C/000197 - IA/0015
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Calcium homeostasis
Therapeutic indication
Calcitonin is indicated for:
Prevention of acute bone loss due to sudden immobilisation such as in patients with recent
osteoporotic fractures
Paget's disease
Hypercalcaemia of malignancy